CLDX
$22
Revenue | $0.7Mn |
Net Profits | $-53.8Mn |
Net Profit Margins | -7740.43% |
Celldex Therapeutics, Inc.’s revenue jumped 345.51% since last year same period to $0.7Mn in the Q1 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -40.85% fall in its revenue since last 3-months.
Celldex Therapeutics, Inc.’s net profit fell -63.97% since last year same period to $-53.8Mn in the Q1 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -14.24% fall in its net profits since last 3-months.
Celldex Therapeutics, Inc.’s net profit margin jumped 63.19% since last year same period to -7740.43% in the Q1 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -93.13% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Current Year | -0.86 |
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.86 - a -24.06% fall from last quarter’s estimates.
Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.86.
Earning Per Share (EPS) | 0 |
Celldex Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2025. This indicates that the Celldex Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-08-07 | -0.86 | 0 | 100% |
2025-05-08 | -0.69 | -0.81 | -17.39% |